Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma
International Journal of Cancer,Volume 0, Issue ja, -Not available-.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: B.
Rousseau
,
A.
Guillemin
,
C.
Duvoux
,
C.
Neuzillet
,
C.
Tlemsani
,
P.
Compagnon
,
D.
Azoulay
,
C.
Salloum
,
A.
Laurent
,
A.
de la Taille
,
L.
Salomon
,
I.
Cholley
,
C.
Haioun
,
J.
Dupuis
,
P.
Wol Source Type: research
More News: Bone Graft | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology